Skip to content

Dissecting the Mechanism of DNA Methylation on the Invasiveness of Pituitary Tumors.

Dissecting the Mechanism of DNA Methylation on the Invasiveness of Pituitary

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05634655
Enrollment
500
Registered
2022-12-02
Start date
2022-01-01
Completion date
2025-01-01
Last updated
2022-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pituitary Tumors

Brief summary

DNA methylation is one of the important ways of protein post-translational modification.Pituitary adenoma (PA) is a benign neuroendocrine tumor that originates from adenohypophysial 45 cells, and accounts for 10%-20% of all primary intracranial tumors. However some PAs can present with high invasiveness and irregular growth, which tend to compresses the optic chiasm and third ventricle, encase the internal carotid artery, and affect hormone secretion from the pituitary gland and hypothalamus. In this study we focus on the mechanism of DNA methylation on the invasiveness of pituitary tumors.

Interventions

OTHERno interventions between two groups

no interventions between two groups

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* 1\) histologically confirmed PAs, 2) Non-function pituitary adenomas

Exclusion criteria

* 1\) Associated with other tumors or serious underlying diseases, 2) the medical records were not complete, or the follow-up data were missing.

Design outcomes

Primary

MeasureTime frameDescription
Residual tumor size1 week after surgeryTumor size was evaluated by postoperative MRI
tumor recurrencethree yearsDuring the follow-up, the tumor recurrence was observed closely

Countries

China

Contacts

Primary ContactWu Qun
2192010@zju.edu.cn13605810393

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026